Archive | Innovator’s Pitch Challenge RSS feed for this section

RESI@JPM Innovation Challenge – Winners Announced

21 Jan

By Nono Hu, Director of Marketing, LSN

Last week, LSN’s Redefining Early Stage Investments (RESI) Conference brought together approximately 350 early stage investors and 300 biotech, medtech and healthcare IT entrepreneurs, our largest crowd to date. The RESI Innovation Challenge received a record number of applicants last fall. The 30 most innovative applicants were hand selected by Life Science Nation’s internal scientific review board and presented their technologies in an exhibition-style format throughout the full-day conference. Here are the top 3 winners!

First Prize Winner: ClearSight

01

ClearSight LLC is commercializing a novel intraocular lens (IOL), the ClearSight IOL, designed to prevent clouding of the lens known as posterior capsular opacification (PCO). PCO is the most frequent surgical complications from cataract surgery, occurring in 25% of patients and costing the U.S. healthcare system $350 million/year. Animal data demonstrates that the ClearSight IOL reduces PCO by 100% in a rabbit model, due to the patent-protected ClearSight IOL design and the addition of a novel microscopic surface texture to prevent cell migration that leads to clouding of the lens. IOLs represent a $1.1 billion U.S. market and $3.7 billion global market.

02

George Ayd, Assistant Vice President, MedMarc; Shravanthi Reddy, COO, ClearSight

 

Second Prize Winner: Eve Medical

03Eve Medical is a Toronto-based medical device company dedicated to improving women’s health. Eve’s core product HerSwab™ makes it easy for women to collect their own samples at home or in clinic to test for common infections that cause cervical cancer, pelvic inflammatory disease and infertility. This saves time, provides privacy and minimizes invasiveness. By reduce barriers to screening, and improving compliance, Eve Medical and HerSwab™ can empower under-served women, improve the reach of existing programs, increase test volumes, and reduce costs for healthcare systems.

04

Michael Quigley, VP of Market Research, LSN; Jessica Ching, CEO, Eve Medical; Dennis Ford, CEO, LSN

 

Third Prize Winner: Briteseed

05The surgeon’s lack of tactile feedback during minimally invasive laparoscopic and robotic surgery leads to difficulty in safely visualizing and manipulating blood vessels, ureters, and bile ducts. Briteseed combats this problem by building smart surgical tools using low-cost optical technology to non-invasively visualize both between and near the jaws of a surgical tool in real time. This combination hardware and software solution is flexible enough to be seamlessly integrated into a spectrum of surgical tools. These smart tools will provide imaging and diagnostic capabilities without interrupting surgical workflow, increasing user adoption. By raising the quality and decreasing overall cost of care, Briteseed provides value to surgeons and the hospital administrations that support them.

06

Michael Quigley, VP of Market Research, LSN; Mayank Vijay, Head of BD and Operations & Co-founder, Briteseed

 

Tags: , , , ,

RESI Innovation Challenge: Participating Startups Announced

17 Dec

By Dennis Ford, Founder & CEO, LSN

dennis-websit

The RESI Innovation Challenge received a record number of applicants this fall. LSN’s scientific review board assessed and ranked all entrants across a wide range of criteria, from scientific novelty to strength of IP, to select the 30 strongest entrants. We’d now like to announce these successful applicants. These entrepreneurs have been selected by LSN’s scientific validation team to receive a presentation space in the exhibit hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. We’re excited to meet all these companies in person in the Exhibitor Hall at RESI, and we hope you’ll join us there to vote for the very best of these cutting-edge life science startups.

IC Logos SF2016

Tags: , , ,

RESI Innovation Challenge Now Accepting Applications

16 Jul

By Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

Shaoyu 10*10

The Redefining Early Stage Investments (RESI) Conference is back in Boston on September 16, and we are looking for innovative life science companies to participate in the RESI Innovation Challenge. If you are a scientist-entrepreneur or fundraising CEO actively looking for raising capital, the RESI Innovation Challenge is for you.

red1

Out of hundreds of applicants, Life Science Nation’s internal scientific review board will choose the top 30 companies to present their technologies in an exhibition-style format throughout the full-day conference. Presenters will gain additional exposure to investors and potential partners by showcasing their companies and products in a poster board format. Unlike traditional 5- to 15-minute pitch presentations that do not allow any real one-on-one interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, which can generate more in-depth and frequent conversations with investors throughout the event.

The RESI Innovation Challenge winners are declared by accumulating “RESI Cash” votes. Each attendee receives “RESI Cash” to “invest” in the Innovation Challenge companies with the most exciting technologies. The top three companies that receive the most investor dollars by the end of the conference will win one of the following prizes:

  • First prize winner of the RESI Innovation Challenge will receive a complimentary subscription to the LSN Investor Platform for a year.
  • Second prize winner will receive two complimentary RESI tickets, to be used within 12 months.
  • Third prize winner will receive one complimentary RESI ticket, to be used within 12 months.

RESIIC-wp

Previous RESI Innovation Challenge first prize winners include Redox (Madison, WI) from RESI@TMCx, Empiriko (Newton, MA) from RESI Boston 3, ORIG3N (Boston, MA), from RESI Boston 2, and Kineta (Seattle, WA) from RESI San Francisco.

Calling All Innovators! RESI Innovation Challenge: Applications Now Open for RESI@TMCx on June 8, 2015

19 Mar

By Jack Fuller, Director of Business Development, LSN

Shaoyu Chang, MD, MPH,  Senior Research Analyst, LSN

JackShaoyu 10*10LSN and the Texas Medical Center Accelerator have partnered to bring the Redefining Early Stage Investments Conference (RESI) to the emerging life science hub of the American Southwest—Houston, TX—on June 8, 2015. We are proud to announce an open call for applications to the RESI Innovation Challenge. Presenting life science companies will have the chance to showcase their innovations to RESI’s audience at the Texas Medical Center’s new life science accelerator TMCx.

If you are a scientist-entrepreneur or fundraising CEO starting to accumulate compelling proof-of-concept animal data or early stage clinical data, the RESI Innovation Challenge is for you. The 30 most innovative applicants will be hand selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge, presenting their technologies in an exhibition-style format throughout the full-day conference. Presenters will gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5- to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors, more frequently throughout the event.

RESI Innovation Challenge winners are determined by vote of all attendees of the conference. Each attendee receives “RESI Cash” tokens to “invest” in the presenting companies with the most exciting technologies. The company that receives the most investor dollars by the end of the conference is crowned the winner. Previous RESI Innovation Challenge first-prize winners include Empiriko (Newton, MA), ORIG3N (Boston, MA), and Kineta (Seattle, WA).

Houston has emerged as a robust life science hub and gateway to Latin America, and Texas Medical Center is spearheading life science innovation in the region. If you are raising capital in biotech, medical devices, diagnostics, or health IT, you can gain investor exposure by putting your groundbreaking technology under the spotlight at RESI@TMCx.

Call-for-Innovation

Winners Announced for the RESI Innovation Challenge

22 Jan

By Nono Hu, Senior Manager, Branding & Messaging, LSN

Nono 2At LSN’s fourth Redefining Early Stage Investments (RESI) Conference, 31 selected medtech and biotech companies participated in a virtual investment contest: The RESI Innovation Challenge. RESI Innovators showcased cutting-edge life science technologies in poster displays throughout the exhibit hall, competing to raise the most RESI Cash.

The winners are in. Congratulations!

First Prize Winner: Kineta

kineta

Kineta is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. The company is focused on the development of novel drug candidates, each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed, NIH-supported research.

kineta 1st

Rob Hedequist, Senior Vice President, Corporate Development, Kineta
 Bill Brah, Executive Director, UMass Venture Development Center

As a first prize winner, Kineta will receive complimentary subscription to the LSN Investor Platform.

Second Prize Winner: Transverse Medical

transverse

Transverse Medical, Inc. is an early stage medical technology company in the evolving and rapidly growing area of Transcatheter Aortic Valve Replacement (TAVR). The TAVR procedure, along with other cardiovascular interventional and surgical procedures, is in need of cerebral protection options. TMI is meeting this need and the challenge of preventing neurocognitive stroke events during TAVR and other such procedures through development of the Point-Guard™ Cerebral Embolic Protection Device.

transverse 2nd

Eric Goslau, CEO, Transverse Medical

Third Prize Winner: Amorphex Therapeutics

amorpex

Amorphex Therapeutics was founded in 2010 to develop and license products for sustained ophthalmic drug delivery using the TODDD™ technology developed by Vista Scientific, LLC. The TODDD™ technology platform is an ocular insert for sustained delivery of drugs to the eye. This patented insert is based on controlled delivery polymer systems and a unique product design utilizing advanced comfort and stability features. In addition to the matrix materials that are used for controlled delivery, the TODDD™ device is also able to incorporate relatively large drug depots for the delivery of specific drugs. This affords the ability to deliver multiple drugs simultaneously. 

amorphex 3th

Robert Thompson, President & CEO, Amorphex Therapeutics
Bill Brah, Executive Director, UMass Venture Development Center
Charles Leahy, Vice President, Clinical Affairs, Amorphex Therapeutics

RESI Innovation Challenge: Scientist-Entrepreneurs Step into the Spotlight at JPM

8 Jan

By Michael Quigley, Director of Research, LSN
 
mike-2The RESI Innovation Challenge is taking place in San Francisco on January 13 and will feature 31 handpicked early stage biotech and medtech innovators from around the globe. These entrepreneurs have each received a presentation space in the exhibit hall for the full day of the conference to present their opportunity to investors and fellow entrepreneurs. LSN has found that companies presenting in this venue interact with more investors—and more frequently—throughout the course of the day than companies making the traditional 15-minute presentation.wpcashTo add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The company that receives the most investor dollars wins. This time, the first prize winner will receive complimentary consulting from LSN. The winner can choose one of the following three projects:
1) A 2- to 3-minute animated video explaining their product
2) A 2-page executive summary
3) A 10- to 12-slide pitch deck
Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!RESI Innovators

RESI Innovation Challenge: Who Knocked it Out of the Park at the Home of the Boston Red Sox?

18 Sep

By Nono Hu, Senior Manager, Branding & Messaging, LSN

Nono 2

At LSN’s third Redefining Early Stage Investments (RESI) Conference, 32 pre-screened medtech and biotech companies competed to be crowned the winner of the RESI Innovation Challenge. All attendees were given RESI Cash with which they could “Invest” in their favorite presenting company at the show and whoever was able to raise the most RESI Cash as deemed the winner.

Scroll down to see the winning companies below (click the logos to visit company websites):

FIRST PLACE:

ORIG3N

ORIG3N, based in Boston, MA, is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver and neurodegenerative indications. These treatments are based upon Nobel Prize winning technology. This will replace the trial & error guess work of treating disease and enable longer, healthier lives.

The company’s executive team is made up of industry veterans with greater than 20 years each in the life sciences marketplace.

ORIG3N Team at RESI 3

ORIG3N Team at RESI 3: Tisha Williams, Representative | Robin Smith, CEO | Kate Blanchard, COO

SECOND PLACE:

SpineThera

SpineThera, based in Minneapolis, MN, develops novel, sustained-release, injectable drugs to treat pain; offering patients and physicians alternatives that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs.

SpineThera-Jeff-

Jeff Missling, CEO

THIRD PLACE:

biosortia

Biosortia Pharmaceuticals, based in Dublin, Ohio, has opened the door to a new frontier of fascinating natural products and potential drug candidates by overcoming the challenges of accessing novel high quality bioactive compounds from uncultuable aquatic microorganisms. Biosortia’s business model is to monetize its developing library through a highly profitable licensing model.

Dieck Kurt-Biosortia

Kurt Dieck, President and CEO

← Older Entries
Newer Entries →